“…Design or methodological publications for the reviewed trials were used to assist in calculating quality scores (where available). One point was awarded for each criterion met, which included (1) adequate description of randomization and concealment process (i.e., describes sequence generation and allocation concealment), (2) baseline demographic and clinical characteristics reported separately for each group (including baseline values of behavioral outcomes), (3) acceptable participant attrition (≤20 % for ≤6 months post-baseline; ≤30 % for >6 months post-baseline), (4) assessor blinding, (5) behavior assessed at ≥6 months postintervention follow-up period (a 6-month duration has been used here as it has been reported as the higher-quality criterion for assessing post-intervention maintenance of outcomes [20,24]), (6) intention-to-treat analyses and an appropriate approach to missing data, (7) potential confounders including baseline level of behavior appropriately accounted for in analyses, (8) power calculation reported and trial adequately powered for at least the primary outcome, (9) use of validated behavioral measurements tools, and (10) summary results presented with estimated effect size (betweengroup difference) and precision estimates. Two researchers independently assessed trials and discrepancies were discussed and verified.…”